ArticleMycopathologia2024
Resistance Profile, Terbinafine Resistance Screening and MALDI-TOF MS Identification of the Emerging Pathogen Trichophyton indotineae.
Article in Mycopathologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Consensus-based Guideline on tinea capitis.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Guideline
- [Multiple itchy, erythrosquamous skin lesions].Dermatologie (Heidelberg, Germany) · 2026Article
- Optimizing MALDI-TOF MS for routine dermatophyte identification, including Trichophyton indotineae.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Global Spread of Trichophyton indotineae Tracked by Mass Spectrometry Identification Network, 2022-2025.Emerging infectious diseases · 2026Article
- Emerging Global Patterns of Terbinafine Resistance inAntibiotics (Basel, Switzerland) · 2026Review
- Evaluation of MALDI-TOF MS for identification of clinical filamentous fungi in a routine mycology laboratory.BMC microbiology · 2026Article
- Article
- The Evolving Landscape of Dermatophytosis in the UAE: Trichophyton indotineae and Related Genotypes.Mycoses · 2026Article
- Clinical and Mycological Profiles of Chronic and Recalcitrant Dermatophytosis: Türkiye, 2022-2024.Mycopathologia · 2026Article
- Trichophyton indotineae: Epidemiology, antifungal resistance and antifungal stewardship strategies.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Majocchi's granuloma of the scalp caused byFrontiers in pediatrics · 2026Article
- Dermatophytosis in Iran: a sharp increase in cases caused byIMA fungus · 2026Article
- A quiet but growing threat: Global perspectives on antifungal resistance and future therapeutic approaches.Indian journal of pharmacology · 2026Review
- Article
- Tinea pseudoimbricata: a narrative literature review and five new cases.Wiener medizinische Wochenschrift (1946) · 2025Review
- National Belgian Study on Terbinafine Resistance inJournal of fungi (Basel, Switzerland) · 2025Article
- Article
- Treatment and diagnostic challenges associated with the novel and rapidly emerging antifungal-resistant dermatophyte,Journal of clinical microbiology · 2025Review
- Terbinafine Resistance inAntibiotics (Basel, Switzerland) · 2025Review
- Trichophyton indotineae Infection, São Paulo, Brazil, 2024.Emerging infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emerging pathogen Trichophyton indotineae, often resistant to terbinafine (TRB), is known to cause severe dermatophytoses such as tinea corporis and tinea cruris. In order to achieve successful treatment for these infections, insight in the resistance profile of T. indotineae strains and rapid, reliable identification is necessary. In this research, a screening medium was tested on T. indotineae strains (n = 20) as an indication tool of TRB resistance. The obtained results were confirmed by antifungal susceptibility testing (AST) for TRB following the in vitro broth microdilution reference method. Additionally, AST was performed for eight other antifungal drugs: fluconazole, itraconazole, voriconazole, ketoconazole, griseofulvin, ciclopirox olamine, naftifine and amorolfine. Forty-five percent of the strains were confirmed to be resistant to terbinafine. The TRB resistant strains showed elevated minimal inhibitory concentration values for naftifine and amorolfine as well. DNA sequencing of the squalene epoxidase-encoding gene showed that TRB resistance was a consequence of missense point mutations in this gene, which led to amino acid substitutions F397L or L393F. MALDI-TOF MS was used as a quick, accurate identification tool for T. indotineae, as it can be challenging to distinguish it from closely related species such as Trichophyton mentagrophytes or Trichophyton interdigitale using morphological characteristics. While MALDI-TOF MS could reliably identify ≥ 95% of the T. indotineae strains (depending on the spectral library), it could not be used to successfully distinguish TRB susceptible from TRB resistant strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.